Inozyme Pharma (NASDAQ:INZY) Price Target Cut to $15.00 by Analysts at Needham & Company LLC

Inozyme Pharma (NASDAQ:INZY - Get Free Report) had its target price decreased by equities research analysts at Needham & Company LLC from $23.00 to $15.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock.

INZY has been the subject of several other research reports. Piper Sandler reduced their price target on shares of Inozyme Pharma from $43.00 to $30.00 and set an "overweight" rating for the company in a research report on Monday, January 13th. HC Wainwright boosted their price target on Inozyme Pharma from $14.00 to $16.00 and gave the stock a "buy" rating in a research note on Friday, January 10th. Wells Fargo & Company dropped their price objective on Inozyme Pharma from $14.00 to $11.00 and set an "overweight" rating on the stock in a research report on Monday, January 13th. Raymond James initiated coverage on Inozyme Pharma in a research report on Thursday, December 12th. They issued an "outperform" rating and a $26.00 target price for the company. Finally, Wedbush reiterated an "outperform" rating and issued a $7.00 price target (down from $12.00) on shares of Inozyme Pharma in a research note on Monday. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $16.89.

Inozyme Pharma Stock Down 7.8 %

NASDAQ:INZY opened at $1.06 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The firm has a market cap of $68.09 million, a P/E ratio of -0.68 and a beta of 1.32. Inozyme Pharma has a fifty-two week low of $1.04 and a fifty-two week high of $7.80. The firm has a 50-day simple moving average of $1.59 and a two-hundred day simple moving average of $3.33.

Institutional Trading of Inozyme Pharma

Several large investors have recently added to or reduced their stakes in the business. Harvest Investment Services LLC bought a new position in Inozyme Pharma in the fourth quarter worth approximately $31,000. Graham Capital Management L.P. purchased a new stake in shares of Inozyme Pharma in the 4th quarter worth $33,000. Virtu Financial LLC bought a new position in Inozyme Pharma in the 3rd quarter worth $64,000. China Universal Asset Management Co. Ltd. bought a new stake in Inozyme Pharma during the fourth quarter valued at about $38,000. Finally, ProShare Advisors LLC purchased a new stake in Inozyme Pharma in the fourth quarter worth about $49,000. 88.30% of the stock is currently owned by institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.

Remove Ads

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.